SAA-3 Protein Accelerates Mammary Involution and Reduces Infection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Non-human mammals, particularly bovines, experience high susceptibility to intra-mammary infections (IMIs) during the dry period due to delayed mammary gland involution and milk stasis, leading to reduced milk production and quality, with existing treatments like antibiotics risking antimicrobial resistance.

Innovation Solution

The use of Serum Amyloid A isoform 3 (SAA-3) protein to enhance mammary gland involution, immune cell recruitment, and bacterial inhibition, potentially replacing or complementing antibiotics to improve udder health and reduce infection risk.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to prevent intra-mammary infections during the dry period, then infection risk is reduced, but antimicrobial resistance develops

Engineering Contradiction:
Improveinfection prevention efficacyVSAvoidantimicrobial resistance
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses SAA-3 protein as an intermediary substance that stimulates the animal's own immune system to produce acute phase proteins, which then provide protective effects against infections. This replaces direct antibiotic intervention with an immune-mediated protective mechanism, preventing antimicrobial resistance while maintaining infection prevention efficacy.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention enables the animal's immune system to serve itself by stimulating endogenous production of protective acute phase proteins through SAA-3 administration. The animal's own immune response becomes the protective mechanism rather than relying on external antibiotics, thus preventing resistance development while maintaining protection.

Inventive Principle:
Principle #25Self-service

2Reliability

If the dry period is extended to allow complete mammary gland involution, then udder health is improved, but productive period is reduced

Engineering Contradiction:
Improveudder healthVSAvoidproductive period duration
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent applies preliminary action by administering SAA-3 protein at the beginning of the dry period to stimulate acute phase protein production and accelerate involution processes. This speeds up the involution timeline, allowing the dry period to be shortened while still achieving complete udder health preparation for the next lactation.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention changes the temporal parameter of the involution process by using SAA-3 to accelerate physiological changes in the mammary gland. This parameter change allows the involution to complete faster, enabling a shorter dry period that maintains udder health improvement while extending the productive period.

Inventive Principle:
Principle #35Parameter changes

3Stability of the object's composition

If milk stasis is allowed during the dry period to induce natural involution, then gland contraction occurs, but susceptibility to bacterial infection increases

Engineering Contradiction:
Improvegland involutionVSAvoidbacterial infection susceptibility
Core Design Contradiction:
Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent introduces SAA-3 protein as an intermediary that stimulates acute phase protein production, which in turn enhances immune cell recruitment and activation. This creates a protective immune barrier during the dry period that prevents bacterial infections even while milk stasis and involution processes occur naturally.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention applies preliminary anti-action by stimulating immune system activation and acute phase protein production at the start of the dry period, before bacterial infections can establish. This pre-emptive immune enhancement counteracts the increased infection risk created by milk stasis, allowing safe involution to proceed.

Inventive Principle:
Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

SAA-3 protein effectively stimulates immune response, enhances metalloproteinase activity, and inhibits bacterial translocation, thereby improving mammary gland involution, reducing IMIs, and maintaining milk quality and production.

Implementation Method 1

SAA-3 protein effectively stimulates immune response

Methodology Applied
Scientific EffectImmune cell recruitment:

Implementation Method 2

The proteolytic destruction of the basement membrane induces apoptosis and involution of mammary gland. There are several proteases involved in the extracellular matrix degradation but basically the matrix metalloproteinases (MMPs) are key enzymes in this process.

Methodology Applied
Scientific EffectProteolytic degradation: Enzyme

Implementation Method 3

SAA-3 protein effectively stimulates immune response, enhances metalloproteinase activity, and inhibits bacterial translocation

Methodology Applied
Scientific EffectBacterial inhibition:

Data Source

PatentEP3003488B1Compositions comprising acute phase proteins for use to improve udder inflammation in non-human mammals
Publication Date: 2020.08.19 CEVA SANTE ANIMALE SA
  • EP3003488B1 patent drawingFigure 1
  • EP3003488B1 patent drawingFigure 2a~2b
  • EP3003488B1 patent drawingFigure 3a~3c

AI summary

The present invention relates to compositions and methods for controlling infections in non-human mammals, particularly intra-mammary infections (IMIs). The invention is particularly suited to control infections and enhance the welfare of non-human mammals, preferably bovine, by improving mammary gland involution during dry off period. The invention is based on the use of acute phase proteins, more preferably Serum Amyloid A (SAA), even more preferably the isoform 3 (SAA-3).